Short Interest in Gilead Sciences Grows By 6.4% (GILD)
Shares of Gilead Sciences (NASDAQ:GILD) saw a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 97,322,157 shares, an increase of 6.4% from the April 15th total of 91,469,585 shares, AR Network reports. Based on an average daily trading volume, of 22,080,628 shares, the days-to-cover ratio is currently 4.4 days. Approximately 6.4% of the company’s shares are sold short.
In other Gilead Sciences news, CFO Robin Washington sold 3,000 shares of Gilead Sciences stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $79.91, for a total value of $239,730.00. Following the transaction, the chief financial officer now directly owns 49,832 shares of the company’s stock, valued at approximately $3,982,075. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
GILD has been the subject of a number of recent research reports. Analysts at Maxim Group raised their price target on shares of Gilead Sciences from $101.00 to $112.00 in a research note on Monday, April 28th. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Gilead Sciences in a research note on Thursday, April 24th. They now have a $78.00 price target on the stock. Finally, analysts at Nomura reiterated a “buy” rating on shares of Gilead Sciences in a research note on Wednesday, April 23rd. They now have a $130.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $89.18.
Gilead Sciences (NASDAQ:GILD) opened at 80.30 on Wednesday. Gilead Sciences has a 52 week low of $46.70 and a 52 week high of $84.88. The stock has a 50-day moving average of $73.58 and a 200-day moving average of $75.20. The company has a market cap of $123.3 billion and a price-to-earnings ratio of 29.76.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, April 22nd. The company reported $1.48 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.85 by $0.63. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the prior year, the company posted $0.48 earnings per share. The company’s quarterly revenue was up 97.5% on a year-over-year basis. Analysts expect that Gilead Sciences will post $6.21 EPS for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.